Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.

Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M, Zago W, Ness DK, Griffith SG, Grundman M, Soto J, Ostrowitzki S, Boess FG, Martin-Facklam M, Quinn JF, Isaacson SH, Omidvar O, Ellenbogen A, Kinney GG.

JAMA Neurol. 2018 Oct 1;75(10):1206-1214. doi: 10.1001/jamaneurol.2018.1487.

2.

C-terminal calcium binding of α-synuclein modulates synaptic vesicle interaction.

Lautenschläger J, Stephens AD, Fusco G, Ströhl F, Curry N, Zacharopoulou M, Michel CH, Laine R, Nespovitaya N, Fantham M, Pinotsi D, Zago W, Fraser P, Tandon A, St George-Hyslop P, Rees E, Phillips JJ, De Simone A, Kaminski CF, Schierle GSK.

Nat Commun. 2018 Feb 19;9(1):712. doi: 10.1038/s41467-018-03111-4.

3.

Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson's Disease (CAPTURE PD): Protocol for a Multicenter Study.

Siepmann T, Pintér A, Buchmann SJ, Stibal L, Arndt M, Kubasch AS, Kubasch ML, Penzlin AI, Frenz E, Zago W, Horváth T, Szatmári S Jr, Bereczki D, Takáts A, Ziemssen T, Lipp A, Freeman R, Reichmann H, Barlinn K, Illigens BM.

Front Neurol. 2017 May 26;8:212. doi: 10.3389/fneur.2017.00212. eCollection 2017.

4.

A bifunctional peptide, "peptope", for pre-targeting antibody 7D8 to systemic amyloid deposits.

Wall JS, Williams A, Foster JS, Martin EB, Richey T, Stuckey A, Macy S, Zago W, Kinney GG, Kennel SJ.

Amyloid. 2017 Mar;24(sup1):22-23. doi: 10.1080/13506129.2017.1295372. No abstract available.

5.

Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy.

Spencer B, Valera E, Rockenstein E, Overk C, Mante M, Adame A, Zago W, Seubert P, Barbour R, Schenk D, Games D, Rissman RA, Masliah E.

Acta Neuropathol Commun. 2017 Jan 13;5(1):7. doi: 10.1186/s40478-016-0410-8.

6.

The Search for a Peripheral Biopsy Indicator of α-Synuclein Pathology for Parkinson Disease.

Lee JM, Derkinderen P, Kordower JH, Freeman R, Munoz DG, Kremer T, Zago W, Hutten SJ, Adler CH, Serrano GE, Beach TG.

J Neuropathol Exp Neurol. 2017 Jan 1;76(1):2-15. doi: 10.1093/jnen/nlw103. Review.

PMID:
28069931
7.

First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers.

Schenk DB, Koller M, Ness DK, Griffith SG, Grundman M, Zago W, Soto J, Atiee G, Ostrowitzki S, Kinney GG.

Mov Disord. 2017 Feb;32(2):211-218. doi: 10.1002/mds.26878. Epub 2016 Nov 25.

8.

2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis .

Renz M, Torres R, Dolan PJ, Tam SJ, Tapia JR, Li L, Salmans JR, Barbour RM, Shughrue PJ, Nijjar T, Schenk D, Kinney GG, Zago W.

Amyloid. 2016 Sep;23(3):168-177. Epub 2016 Aug 5.

9.

Pilomotor function is impaired in patients with Parkinson's disease: A study of the adrenergic axon-reflex response and autonomic functions.

Siepmann T, Frenz E, Penzlin AI, Goelz S, Zago W, Friehs I, Kubasch ML, Wienecke M, Löhle M, Schrempf W, Barlinn K, Siegert J, Storch A, Reichmann H, Illigens BM.

Parkinsonism Relat Disord. 2016 Oct;31:129-134. doi: 10.1016/j.parkreldis.2016.08.001. Epub 2016 Aug 11.

PMID:
27569843
10.

Monitoring Blood-Brain Barrier Integrity Following Amyloid-β Immunotherapy Using Gadolinium-Enhanced MRI in a PDAPP Mouse Model.

Blockx I, Einstein S, Guns PJ, Van Audekerke J, Guglielmetti C, Zago W, Roose D, Verhoye M, Van der Linden A, Bard F.

J Alzheimers Dis. 2016 Sep 6;54(2):723-35. doi: 10.3233/JAD-160023.

PMID:
27567811
11.

Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin.

Higaki JN, Chakrabartty A, Galant NJ, Hadley KC, Hammerson B, Nijjar T, Torres R, Tapia JR, Salmans J, Barbour R, Tam SJ, Flanagan K, Zago W, Kinney GG.

Amyloid. 2016 Jun;23(2):86-97. doi: 10.3109/13506129.2016.1148025. Epub 2016 Mar 16.

12.

Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.

Games D, Valera E, Spencer B, Rockenstein E, Mante M, Adame A, Patrick C, Ubhi K, Nuber S, Sacayon P, Zago W, Seubert P, Barbour R, Schenk D, Masliah E.

J Neurosci. 2014 Jul 9;34(28):9441-54. doi: 10.1523/JNEUROSCI.5314-13.2014.

13.

Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease.

Tóth G, Gardai SJ, Zago W, Bertoncini CW, Cremades N, Roy SL, Tambe MA, Rochet JC, Galvagnion C, Skibinski G, Finkbeiner S, Bova M, Regnstrom K, Chiou SS, Johnston J, Callaway K, Anderson JP, Jobling MF, Buell AK, Yednock TA, Knowles TP, Vendruscolo M, Christodoulou J, Dobson CM, Schenk D, McConlogue L.

PLoS One. 2014 Feb 14;9(2):e87133. doi: 10.1371/journal.pone.0087133. eCollection 2014. Erratum in: PLoS One. 2014;9(5):e99274.

14.

Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities.

Zago W, Schroeter S, Guido T, Khan K, Seubert P, Yednock T, Schenk D, Gregg KM, Games D, Bard F, Kinney GG.

Alzheimers Dement. 2013 Oct;9(5 Suppl):S105-15. doi: 10.1016/j.jalz.2012.11.010. Epub 2013 Apr 11.

PMID:
23583235
15.

Laminin-411 is a vascular ligand for MCAM and facilitates TH17 cell entry into the CNS.

Flanagan K, Fitzgerald K, Baker J, Regnstrom K, Gardai S, Bard F, Mocci S, Seto P, You M, Larochelle C, Prat A, Chow S, Li L, Vandevert C, Zago W, Lorenzana C, Nishioka C, Hoffman J, Botelho R, Willits C, Tanaka K, Johnston J, Yednock T.

PLoS One. 2012;7(7):e40443. doi: 10.1371/journal.pone.0040443. Epub 2012 Jul 6.

16.

Quantifying amyloid beta (Aβ)-mediated changes in neuronal morphology in primary cultures: implications for phenotypic screening.

Nguyen L, Wright S, Lee M, Ren Z, Sauer JM, Hoffman W, Zago W, Kinney GG, Bova MP.

J Biomol Screen. 2012 Jul;17(6):835-42. doi: 10.1177/1087057112441972. Epub 2012 Apr 2.

PMID:
22473881
17.

Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific.

Zago W, Buttini M, Comery TA, Nishioka C, Gardai SJ, Seubert P, Games D, Bard F, Schenk D, Kinney GG.

J Neurosci. 2012 Feb 22;32(8):2696-702. doi: 10.1523/JNEUROSCI.1676-11.2012.

18.

Deletion of Shp2 tyrosine phosphatase in muscle leads to dilated cardiomyopathy, insulin resistance, and premature death.

Princen F, Bard E, Sheikh F, Zhang SS, Wang J, Zago WM, Wu D, Trelles RD, Bailly-Maitre B, Kahn CR, Chen Y, Reed JC, Tong GG, Mercola M, Chen J, Feng GS.

Mol Cell Biol. 2009 Jan;29(2):378-88. doi: 10.1128/MCB.01661-08. Epub 2008 Nov 10.

19.

Modulation of NMDA receptor properties and synaptic transmission by the NR3A subunit in mouse hippocampal and cerebrocortical neurons.

Tong G, Takahashi H, Tu S, Shin Y, Talantova M, Zago W, Xia P, Nie Z, Goetz T, Zhang D, Lipton SA, Nakanishi N.

J Neurophysiol. 2008 Jan;99(1):122-32. Epub 2007 Nov 14.

20.

Takusan: a large gene family that regulates synaptic activity.

Tu S, Shin Y, Zago WM, States BA, Eroshkin A, Lipton SA, Tong GG, Nakanishi N.

Neuron. 2007 Jul 5;55(1):69-85.

21.

Hypoxia enhances S-nitrosylation-mediated NMDA receptor inhibition via a thiol oxygen sensor motif.

Takahashi H, Shin Y, Cho SJ, Zago WM, Nakamura T, Gu Z, Ma Y, Furukawa H, Liddington R, Zhang D, Tong G, Chen HS, Lipton SA.

Neuron. 2007 Jan 4;53(1):53-64.

22.

Nicotinic signal transduction machinery.

Berg DK, Conroy WG, Liu Z, Zago WM.

J Mol Neurosci. 2006;30(1-2):149-52.

PMID:
17192663
23.

BDNF up-regulates alpha7 nicotinic acetylcholine receptor levels on subpopulations of hippocampal interneurons.

Massey KA, Zago WM, Berg DK.

Mol Cell Neurosci. 2006 Dec;33(4):381-8. Epub 2006 Oct 9.

24.

Nicotinic activity stabilizes convergence of nicotinic and GABAergic synapses on filopodia of hippocampal interneurons.

Zago WM, Massey KA, Berg DK.

Mol Cell Neurosci. 2006 Mar;31(3):549-59. Epub 2006 Jan 5.

PMID:
16403644
25.
26.

Melatonin nocturnal surge modulates nicotinic receptors and nicotine-induced [3H]glutamate release in rat cerebellum slices.

Markus RP, Santos JM, Zago W, Reno LA.

J Pharmacol Exp Ther. 2003 May;305(2):525-30. Epub 2003 Jan 24.

PMID:
12606693
27.
29.

Melatonin modulation of presynaptic nicotinic acetylcholine receptors in the rat vas deferens.

Markus RP, Zago WM, Carneiro RC.

J Pharmacol Exp Ther. 1996 Oct;279(1):18-22.

PMID:
8858970

Supplemental Content

Support Center